title: Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials.
authors.affiliation: Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif.
authors.forename: Carlos
authors.initials: C
authors.lastname: Iribarren
authors.affiliation: RTI Health Solutions, Research Triangle Park, NC.
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Rothman
authors.affiliation: Genentech, Inc, South San Francisco, Calif.
authors.forename: Mary S
authors.initials: MS
authors.lastname: Bradley
authors.affiliation: Genentech, Inc, South San Francisco, Calif.
authors.forename: Gillis
authors.initials: G
authors.lastname: Carrigan
authors.affiliation: Genentech, Inc, South San Francisco, Calif.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Eisner
authors.affiliation: Genentech, Inc, South San Francisco, Calif. Electronic address: chen.hubert@gene.com.
authors.forename: Hubert
authors.initials: H
authors.lastname: Chen
mesh_terms: D018927:Anti-Asthmatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality; D002561:Cerebrovascular Disorders / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality; D002648:Child; D004311:Double-Blind Method; D006801:Humans; D006967:Hypersensitivity / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D000069444:Omalizumab / Q000009:adverse effects* / Q000627:therapeutic use; D015990:Placebo Effect; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
chemical_list: D018927:Anti-Asthmatic Agents; D000069444:Omalizumab